Please login to the form below

Not currently logged in
Email:
Password:

Santhera

This page shows the latest Santhera news and features for those working in and with pharma, biotech and healthcare.

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

CHMP hands Santhera second ‘ no’ in Duchenne muscular dystrophy. Swiss biopharma says it will re-file Raxone for the licence extension. ... European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Shires's Jeffrey Jonas to lead Sage Shires's Jeffrey Jonas to lead Sage

    The other key appointments are AstraZeneca's Stephen Kanes as chief medical officer and Santhera's Kimi Iguchi as chief financial officer. ... Iguchi joins from her role as chief operating officer, North America, for Santhera.

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    Santhera CEO Klaus Schollmeier joins SuppreMol. He has experience at ING BHF-Bank, BASF, Knoll and Abbott. ... Former CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Solaris Health

    GlaxoSmithKline. Ipsen. Meda. PM Society. Santhera. Visufarma. See our Thought Leadership article reviewing pressures at both end of the cost spectrum and considering the likely impact on clinicians and patients.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics